Helus Pharma stock tumbles 21% despite positive trial results
Helus Pharma (NASDAQ: HELP) shares dropped 21% on Monday, despite reporting positive Phase 3 trial results for HLP003 in treating major depressive disorder. The drug met primary and secondary endpoints, showing significant improvement over placebo. The company plans to release further trial results in late 2027.
How this was made
The 30-second read
Why it matters
Positive Phase 3 results were offset by a steep share decline, indicating market doubt.
Market read
The trial outcome is material for HELP and may influence sentiment toward similar biotech firms.
What to watch
Potential for future regulatory approval and market expansion if longer‑term data remain positive.
Background
Helus Pharma (NASDAQ: HELP) is a clinical‑stage biotech focused on depression therapies.
Ticker impact
Helus Pharma shares dropped 21% on the day after the company announced positive Phase 3 trial results for HLP003.
likely pressure as investors question safety profile and commercial prospects
Positive trial data is usually bullish, but the sharp sell‑off signals concerns that outweigh the headline, creating short‑term downside risk.
Market effects
May raise caution for other depression‑treatment biotech stocks.
Limited to US biotech sector.
Modest; primarily affects investors tracking mental‑health drug pipelines.
Counterpoint
The data could eventually support a rally if safety concerns are addressed.
Key entities
- companyHelus Pharma Inc.
Biotech developer of HLP003 for major depressive disorder.




